Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Theravance Bio Ord (TBPH)

Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance Zacks Investment Research - Mon Nov 11, 7:52AM CST

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 56.09 (+3.29%)
TBPH : 9.97 (+0.50%)
MDGL : 317.09 (+0.93%)
LRMR : 6.08 (-4.70%)
CPRX : 21.15 (-1.12%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
5 Small Drug Stocks to Buy as Trump Gets Re-Elected Zacks Investment Research - Fri Nov 8, 7:30AM CST

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 56.09 (+3.29%)
TBPH : 9.97 (+0.50%)
MDGL : 317.09 (+0.93%)
LRMR : 6.08 (-4.70%)
CPRX : 21.15 (-1.12%)
Theravance Bio: Q4 Earnings Snapshot AP - Mon Feb 26, 3:39PM CST

Theravance Bio: Q4 Earnings Snapshot

TBPH : 9.97 (+0.50%)
Theravance Bio: Q3 Earnings Snapshot AP - Tue Nov 7, 2023

Theravance Bio: Q3 Earnings Snapshot

TBPH : 9.97 (+0.50%)
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023 PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close...

TBPH : 9.97 (+0.50%)
Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference...

TBPH : 9.97 (+0.50%)
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders PR Newswire - Mon Aug 28, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic...

TBPH : 9.97 (+0.50%)
Theravance Bio: Q2 Earnings Snapshot AP - Mon Aug 7, 2023

Theravance Bio: Q2 Earnings Snapshot

TBPH : 9.97 (+0.50%)
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire - Mon Aug 7, 2023

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...

TBPH : 9.97 (+0.50%)
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 PR Newswire - Mon Jul 24, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market...

TBPH : 9.97 (+0.50%)

Barchart Exclusives

Using Option To Generate Extra Income From Your Bond Investments Barchart - 4 minutes ago
With markets looking increasingly volatile, investors might be more interested in generating income rather than capital gains. Bond investments have seen significant capital losses in recent months as inflation concerns continue to have investors anxious. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot